Last reviewed · How we verify
AzaSite Eye Drops
AzaSite is an azithromycin ophthalmic suspension that reduces bacterial load and inflammatory mediators in the eye to treat bacterial conjunctivitis and meibomian gland dysfunction.
AzaSite is an azithromycin ophthalmic suspension that reduces bacterial load and inflammatory mediators in the eye to treat bacterial conjunctivitis and meibomian gland dysfunction. Used for Bacterial conjunctivitis, Meibomian gland dysfunction (dry eye disease).
At a glance
| Generic name | AzaSite Eye Drops |
|---|---|
| Also known as | AzaSite (azithromycin ophthalmic solution) |
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Macrolide antibiotic |
| Target | Bacterial 50S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Azithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. In addition to its antimicrobial activity, azithromycin has anti-inflammatory properties that help reduce ocular surface inflammation and improve tear film stability, making it effective for both infectious and inflammatory ocular conditions.
Approved indications
- Bacterial conjunctivitis
- Meibomian gland dysfunction (dry eye disease)
Common side effects
- Eye irritation
- Conjunctival hyperemia
- Ocular discomfort
- Blurred vision
Key clinical trials
- Effect of Topical Azithromycin on Tear Film Thickness in Patients With Meibomian Gland Dysfunction (PHASE4)
- Comparing Efficacy of Tea Tree Oil Versus Topical Azithromycin in Treating Dry Eye (PHASE1, PHASE2)
- Efficacy and Safety Study of a Steroid/Antibiotic Combination Eyedrop to Treat Non-Bacterial Blepharitis (PHASE3)
- Efficacy of Over the Counter (OTC) Povidone-Ioldine 5% for Treatment of Acute or Chronic Blepharitis (NA)
- Tear Concentrations and Pharmacokinetics of Azithromycin Eye Drops in Healthy Volunteers (PHASE1)
- Local Pharmacokinetics of Azithromycin Eye Drops in Healthy Volunteers (PHASE1)
- Study to Determine the Effect of Azasite on Corneal Surface Irregularity (PHASE2)
- Antibiotic Steroid Combination Compared With Individual Administration in the in the Treatment of Ocular Inflammation and Infection (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AzaSite Eye Drops CI brief — competitive landscape report
- AzaSite Eye Drops updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI